{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:16:24Z","timestamp":1786396584945,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With the advent of novel gene therapies, rare genetic diseases once lacking treatments are now being considered for newborn screening programmes (NBS). Wilson and Jungner criteria (drawn on worldwide to guide screening programme evaluation) necessitate effective interventions for a recommendation of screening. Spinal muscular atrophy (SMA) is an example of a condition for which the case for NBS has rapidly gathered pace\u00a0in recent years. With the introduction of disease-modifying therapies (that are most efficacious when delivered pre-symptomatically), many countries are now piloting or implementing SMA NBS. Despite this, the acceptability of SMA NBS remains underexplored. To address this gap, surveys and interviews were conducted with four key groups: i) general public, ii) SMA families, iii) parents of screened babies iv) healthcare professionals. Survey responses from 9,511 respondents were analysed: 5,604 from the public, 250 from SMA families, 3,541 from parents and 116 from healthcare professionals. Fifty-three qualitative interviews were conducted with 56 participants: 10 public; 12 SMA parents; 9 adults with SMA; 9 parents of screened babies (including one positive result) and 16 healthcare professionals. Support for SMA NBS was found to be consistently high: 90% of public, 99% of SMA parents and adults, 98% of parents of screened babies and 97% of healthcare professionals supported its\u00a0national implementation. Concerns centred on the impact of diagnoses through NBS, anxiety and treatment ineligabilty\u00a0for adult-onset SMA. However, these were not considered barriers. SMA NBS is widely acceptable to relevant stakeholder groups, though rapid, comprehensive and\u00a0high-quality support for families is essential following diagnosis.<\/jats:p>","DOI":"10.1038\/s41431-026-02096-9","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:43:14Z","timestamp":1775752994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acceptability of newborn screening for spinal muscular atrophy: views of the UK public, screened families, health professionals and the SMA community"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-6276","authenticated-orcid":false,"given":"Felicity","family":"Boardman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5743-0725","authenticated-orcid":false,"given":"Rebecca","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-9383","authenticated-orcid":false,"given":"Corinna","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jimd.12650","volume":"46","author":"U Spiekerkoetter","year":"2023","unstructured":"Spiekerkoetter U, Bick D, Scott R, Hopkins H, Krones T, Gross ES, et al. Genomic newborn screening: are we entering a new era of screening? J Inherit Metab Dis. 2023;46:778\u201395.","journal-title":"J Inherit Metab Dis"},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s12687-025-00788-1","volume":"16","author":"SM Rankin","year":"2025","unstructured":"Rankin SM, Marskell L, Hamad L, Machin L. The UK National screening committee, the newborn genomes programme, and the ethical conundrum for UK newborn screening. J Community Genet. 2025;16:589\u2013601.","journal-title":"J Community Genet"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(25)00048-0","volume":"405","author":"L Servais","year":"2025","unstructured":"Servais L, Dangouloff T, Muntoni F, Scoto M, Baranello G. Spinal muscular atrophy in the UK: the human toll of slow decisions. Lancet. 2025;405:619\u201320.","journal-title":"Lancet"},{"key":"2096_CR4","unstructured":"Genetic Alliance UK. Time to decide: Learning from international approaches to newborn screening decision-making. 2025 https:\/\/geneticalliance.org.uk\/wp-content\/uploads\/2025\/07\/Time-to-decide-Learning-from-international-approaches-newborn-screening-decision-making_Highres-3.pdf (accessed 15 Aug2025)."},{"key":"2096_CR5","unstructured":"UK National Screening Committee GU. Criteria for a population screening programme. 2022. https:\/\/www.gov.uk\/government\/publications\/evidence-review-criteria-national-screening-programmes\/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme (accessed 6 Feb2026)."},{"key":"2096_CR6","unstructured":"SMA NBS Alliance. White Paper 2024 - Spinal muscular atrophy: Screen at birth, save lives. 2024 https:\/\/nbs-alliance-assets.gpm.digital\/SMA_White_Paper_NBSA_2024_EN_e91bb03c79.pdf (accessed 6 Feb2026)."},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, Behrens M, Wei\u00df C, Johannsen J, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy. JAMA Pediatr. 2024;178:540.","journal-title":"JAMA Pediatr"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","volume":"22","author":"DM Kay","year":"2020","unstructured":"Kay DM, Stevens CF, Parker A, Saavedra-Matiz CA, Sack V, Chung WK, et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med. 2020;22:1296\u2013302.","journal-title":"Genet Med"},{"key":"2096_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2021.100899","volume":"38","author":"RJ Butterfield","year":"2021","unstructured":"Butterfield RJ. Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol. 2021;38:100899.","journal-title":"Semin Pediatr Neurol"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11\u201325.","journal-title":"Appl Clin Genet"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15117","volume":"64","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Kariyawasam DST, Best S, Wiley V, Farrar MA. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol. 2022;64:625\u201332.","journal-title":"Dev Med Child Neurol"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-200475","volume":"7","author":"W M\u00fcller-Felber","year":"2020","unstructured":"M\u00fcller-Felber W, Vill K, Schwartz O, Gl\u00e4ser D, Nennstiel U, Wirth B, et al. Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening \u2013 opportunity or burden? J Neuromuscul Dis. 2020;7:109\u201317.","journal-title":"J Neuromuscul Dis"},{"key":"2096_CR13","doi-asserted-by":"publisher","unstructured":"Gerin L, Ropars J, Garcia-Uzquiano R, G\u00f3mez-Garc\u00eda De la Banda M, Saugier-Veber P, Desguerre I, et al. Spectrum of Phenotypes in SMA Patients With 4 SMN2 Copies in the French Population. Neurol Genet. 2025;11:200222. https:\/\/doi.org\/10.1212\/NXG.0000000000200222.","DOI":"10.1212\/NXG.0000000000200222"},{"key":"2096_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000530","volume":"6","author":"I Cusc\u00f3","year":"2020","unstructured":"Cusc\u00f3 I, Bernal S, Blasco-P\u00e9rez L, Calucho M, Alias L, Fuentes-Prior P, et al. Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy. Neurol Genet. 2020;6:e530.","journal-title":"Neurol Genet"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpn.2024.08.006","volume":"53","author":"EF Tizzano","year":"2024","unstructured":"Tizzano EF, Quijano-Roy S, Servais L, Parsons JA, Aharoni S, Lakhotia A, et al. Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec. Eur J Paediatr Neurol. 2024;53:18\u201324.","journal-title":"Eur J Paediatr Neurol"},{"key":"2096_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100742","volume":"33","author":"DST Kariyawasam","year":"2021","unstructured":"Kariyawasam DST, D\u2019Silva AM, Vetsch J, Wakefield CE, Wiley V, Farrar MA. We needed this\u201d: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. EClinicalMedicine. 2021;33:100742.","journal-title":"EClinicalMedicine"},{"key":"2096_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JND-230082","volume":"11","author":"AP Meyer","year":"2024","unstructured":"Meyer AP, Connolly AM, Vannatta K, Hacker N, Hatfield A, Decipeda A, et al. Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy. J Neuromuscul Dis. 2024;11:129\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"2096_CR18","doi-asserted-by":"publisher","unstructured":"Mak CM, Lee JKH, Wong JCL, Law CY, Chan CHT, Yeung CW, et al. Views of the Public and Healthcare Professionals on Newborn Screening for Spinal Muscular Atrophy and the Potential for Detecting Adult-Onset Types in Patients-in-Waiting in Hong Kong. Cureus 2025. https:\/\/doi.org\/10.7759\/cureus.79190.","DOI":"10.7759\/cureus.79190"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/children8080694","volume":"8","author":"T Lee","year":"2021","unstructured":"Lee T, Tokunaga S, Taniguchi N, Fujino T, Saito M, Shimomura H, et al. Views of the general population on newborn screening for spinal muscular atrophy in Japan. Children. 2021;8:694.","journal-title":"Children"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2016.09.008","volume":"66","author":"P-J Lin","year":"2017","unstructured":"Lin P-J, Yeh W-S, Neumann PJ. Willingness to pay for a newborn screening test for spinal muscular atrophy. Pediatr Neurol. 2017;66:69\u201375.","journal-title":"Pediatr Neurol"},{"key":"2096_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/mus.24100","volume":"49","author":"MF Wood","year":"2014","unstructured":"Wood MF, Hughes SC, Hache LP, Naylor EW, Abdel-Hamid HZ, Barmada MM, et al. Parental attitudes toward newborn screening for Duchenne\/Becker muscular dystrophy and spinal muscular atrophy. Muscle Nerve. 2014;49:822\u20138.","journal-title":"Muscle Nerve"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/ajmg.a.38220","volume":"173","author":"FK Boardman","year":"2017","unstructured":"Boardman FK, Young PJ, Griffiths FE. Newborn screening for spinal muscular atrophy: the views of affected families and adults. Am J Med Genet A. 2017;173:1546\u201361.","journal-title":"Am J Med Genet A"},{"key":"2096_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mgg3.353","volume":"6","author":"FK Boardman","year":"2018","unstructured":"Boardman FK, Sadler C, Young PJ. Newborn genetic screening for spinal muscular atrophy in the UK: the views of the general population. Mol Genet Genom Med. 2018;6:99\u2013108.","journal-title":"Mol Genet Genom Med"},{"key":"2096_CR24","first-page":"A200.1","volume":"108","author":"R Horton","year":"2023","unstructured":"Horton R, Volkers A, Betts C, Ramdas S, Servais L. 819 Feasibility and uptake of newborn screening for spinal muscular atrophy in the UK. Arch Dis Child. 2023;108:A200.1\u2013A200.","journal-title":"Arch Dis Child"},{"key":"2096_CR25","unstructured":"Spinal Muscular Atrophy UK. The Oxford -Thames Valley-Wessex SMA Newborn Screening Study. 2025. https:\/\/smauk.org.uk\/advocacy-and-campaigning\/newborn-screening\/the-oxford-thames-valley-wessex-based-sma-newborn-screening-study\/ (accessed 18 Mar2026)."},{"key":"2096_CR26","unstructured":"Creswell JW, Plano Clark VL Designing and conducting mixed methods research. 3rd ed. SAGE Publications, 2017."},{"key":"2096_CR27","doi-asserted-by":"publisher","unstructured":"Boardman FK, Hale R, Gohel R, Young PJ Preventing lives affected by hemophilia: a mixed methods study of the views of adults with hemophilia and their families toward genetic screening. Mol Genet Genomic Med. 2019;7:618. https:\/\/doi.org\/10.1002\/mgg3.618.","DOI":"10.1002\/mgg3.618"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/jgc4.1231","volume":"29","author":"FK Boardman","year":"2020","unstructured":"Boardman FK, Clark C, Jungkurth E, Young PJ. Social and cultural influences on genetic screening programme acceptability: a mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK. J Genet Couns. 2020;29:1026\u201340.","journal-title":"J Genet Couns"},{"key":"2096_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41431-021-00962-2","volume":"30","author":"FK Boardman","year":"2022","unstructured":"Boardman FK, Clark CC. What is a \u2018serious\u2019 genetic condition? The perceptions of people living with genetic conditions. Eur J Hum Genet. 2022;30:160\u20139.","journal-title":"Eur J Hum Genet"},{"key":"2096_CR30","doi-asserted-by":"publisher","unstructured":"Boardman F, Roberts J, Clark C, Onuegbu C, Harris B, Seers K, et al. Qualitative Remote Data Collection Guidance 2024. Coventry. 2024 https:\/\/doi.org\/10.31273\/9781911675174.","DOI":"10.31273\/9781911675174"},{"key":"2096_CR31","unstructured":"Saldan\u0303a J The coding manual for qualitative researchers. 2nd ed. SAGE Publications: London, 2013."},{"key":"2096_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5:80\u201392.","journal-title":"Int J Qual Methods"},{"key":"2096_CR33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1468794106058870","volume":"6","author":"J Moran-Ellis","year":"2006","unstructured":"Moran-Ellis J, Alexander VD, Cronin A, Dickinson M, Fielding J, Sleney J, et al. Triangulation and integration: processes, claims and implications. Qualitative Res. 2006;6:45\u201359.","journal-title":"Qualitative Res"},{"key":"2096_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1086\/JCE200920406","volume":"20","author":"EG Epstein","year":"2009","unstructured":"Epstein EG, Hamric AB. Moral distress, moral residue, and the crescendo effect. J Clin Ethics. 2009;20:330\u201342.","journal-title":"J Clin Ethics"},{"key":"2096_CR35","unstructured":"Genomics England. The Generation Study Protocol v3.0. 2023 https:\/\/files.genomicsengland.co.uk\/documents\/Newborns\/Generation-Study-Protocol_nc.pdf (accessed 6 Feb2026)."},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1542\/peds.2010-3743","volume":"129","author":"ECF Caga-anan","year":"2012","unstructured":"Caga-anan ECF, Smith L, Sharp RR, Lantos JD. Testing children for adult-onset genetic diseases. Pediatrics. 2012;129:163\u20137.","journal-title":"Pediatrics"},{"key":"2096_CR37","unstructured":"Collyer Merritt E Infected blood scandal: Background, impacts, inquiry outcomes and compensation. UK Parliament, House of Lords Library. 2024. https:\/\/lordslibrary.parliament.uk\/infected-blood-scandal-background-impacts-interim-compensation-and-inquiry-outcomes\/ (accessed 6 Feb2026)."},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/08964289.2019.1585327","volume":"45","author":"W Powell","year":"2019","unstructured":"Powell W, Richmond J, Mohottige D, Yen I, Joslyn A, Corbie-Smith G. Medical mistrust, racism, and delays in preventive health screening among African-American men. Behav Med. 2019;45:102\u201317.","journal-title":"Behav Med"},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1017\/S0266462318003471","volume":"34","author":"QN Hong","year":"2018","unstructured":"Hong QN, Pluye P, F\u00e0bregues S, Bartlett G, Boardman F, Cargo M, et al. VP26 a critical appraisal tool for systematic mixed studies reviews. Int J Technol Assess Health Care. 2018;34:166\u2013166.","journal-title":"Int J Technol Assess Health Care"},{"key":"2096_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/medethics-2011-100040","volume":"38","author":"SG Nicholls","year":"2012","unstructured":"Nicholls SG. Proceduralisation, choice and parental reflections on decisions to accept newborn bloodspot screening. J Med Ethics. 2012;38:299\u2013303.","journal-title":"J Med Ethics"},{"key":"2096_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/ijns11010005","volume":"11","author":"JE Klapwijk","year":"2025","unstructured":"Klapwijk JE, Gitsels-van der Wal J, Martin L, Verschoof-Puite RK, Elsinghorst E, Henneman L. Maternity care providers\u2019 experiences with providing information on newborn bloodspot screening during pregnancy: a Dutch survey study. Int J Neonatal Screen. 2025;11:5.","journal-title":"Int J Neonatal Screen"},{"key":"2096_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","volume":"20","author":"JN Kraszewski","year":"2018","unstructured":"Kraszewski JN, Kay DM, Stevens CF, Koval C, Haser B, Ortiz V, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20:608\u201313.","journal-title":"Genet Med"},{"key":"2096_CR43","unstructured":"Office for Health Improvement & Disparities. Population screening: review of interventions to improve participation among underserved groups. 2022 https:\/\/www.gov.uk\/government\/publications\/population-screening-improving-participation-in-underserved-groups\/population-screening-review-of-interventions-to-improve-participation-among-underserved-groups (accessed 14 Aug2025)."},{"key":"2096_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill K, Schwartz O, Blaschek A, Gl\u00e4ser D, Nennstiel U, Wirth B, et al. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis. 2021;16:153.","journal-title":"Orphanet J Rare Dis"},{"key":"2096_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99496-2","volume":"11","author":"F Boemer","year":"2021","unstructured":"Boemer F, Caberg J-H, Beckers P, Dideberg V, di Fiore S, Bours V, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021;11:19922.","journal-title":"Sci Rep"},{"key":"2096_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/ijns11020032","volume":"11","author":"SA Sandelowsky","year":"2025","unstructured":"Sandelowsky SA, McEwen A, Russell J, Boggs K, Junek R, Ellaway C, et al. An explorative qualitative study of the role of a genetic counsellor to parents receiving a diagnosis after a positive newborn bloodspot screening. Int J Neonatal Screen. 2025;11:32.","journal-title":"Int J Neonatal Screen"},{"key":"2096_CR47","doi-asserted-by":"crossref","unstructured":"Leach M, Finanger E, Izumi S 155P The experience of parents as they make treatment decisions for their child with spinal muscular atrophy and the factors that influence these decisions: a narrative review. In: Neuromuscular Disorders. 2024:104441.590.","DOI":"10.1016\/j.nmd.2024.07.599"},{"key":"2096_CR48","doi-asserted-by":"publisher","unstructured":"Boursange S, Araneda M, Stalens C, Desguerre I, Barnerias C, Nougues M-C, et al. Parents\u2019 dilemma: a therapeutic decision for children with spinal muscular atrophy (SMA) type 1. Front Pediatr. 2022;10:1062390. https:\/\/doi.org\/10.3389\/fped.2022.1062390.","DOI":"10.3389\/fped.2022.1062390"},{"key":"2096_CR49","doi-asserted-by":"crossref","unstructured":"Goedeker N, Dierker A, Felker M, Lakhotia A, Rogers A, Zaidman C 148P Rapid risdiplam initiation in newborns with spinal muscular atrophy (SMA): a multicenter, retrospective cohort study. Neuromuscular Disord. 2024;43:104441.583.","DOI":"10.1016\/j.nmd.2024.07.592"},{"key":"2096_CR50","unstructured":"Breeze AA Comparing Psychosocial Impacts of Spinal Muscular Atrophy Diagnoses Before and After Newborn Screening Implementation. Master of Science and Master of Public Health thesis. University of Pittsburgh; 2023. d-scholarship.pitt.edu\/concern\/etds\/a63caa1e-fb20-4f06-8005-2e30194308a7."},{"key":"2096_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114367","volume":"287","author":"AL White","year":"2021","unstructured":"White AL, Boardman F, McNiven A, Locock L, Hinton L. Absorbing it all: a meta-ethnography of parents\u2019 unfolding experiences of newborn screening. Soc Sci Med. 2021;287:114367.","journal-title":"Soc Sci Med"},{"key":"2096_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22:557\u201365.","journal-title":"Genet Med"},{"key":"2096_CR53","doi-asserted-by":"publisher","unstructured":"Tutty E, Kanga-Parabia A, Kugenthiran N, Caruana J, Downie L, Gaff C, et al. Parental experiences of receiving genomic newborn screening results: findings from the BabyScreen+ study. Eur J Hum Genet. 2026. https:\/\/doi.org\/10.1038\/s41431-026-02036-7.","DOI":"10.1038\/s41431-026-02036-7"},{"key":"2096_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/ijns10030049","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, et al. Systematic review of newborn screening programmes for spinal muscular atrophy. Int J Neonatal Screen. 2024;10:49.","journal-title":"Int J Neonatal Screen"},{"key":"2096_CR55","unstructured":"Harcombe J. SMA Screening ISE partnership board updated on NIHR research call. UK National Screening Committee, GOV UK. 2025. https:\/\/nationalscreening.blog.gov.uk\/2025\/06\/10\/sma-screening-ise-partnership-board-updated-on-nihr-research-call\/ (accessed 6 Feb2026)."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02096-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02096-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:43:17Z","timestamp":1775752997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02096-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":55,"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02096-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8881933\/v1","asserted-by":"object"}]},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FB sits on the Foetal, Maternal and Child Health Reference Group of the UK National Screening Committee. No other authors have conflicts to declare. Novartis Gene Therapies had no input into the study design, data collection instruments, data analysis, interpretation or findings of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all participants. Approval for data collection with the public, HCPs and SMA families was granted 18\/11\/22 by the Biomedical and Scientific Research Ethics Committee, University of Warwick. Approval for data collection with families offered screening through the Thames Valley Pilot Study was granted by the Health Research Authority through NHS REC 21\/SC\/0394 on 15\/8\/23.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}